Noema Pharma, a clinical-stage biotech company focusing on CNS disorders, has appointed Michael Samar as Chief Financial Officer. In addition, Volker Knappertz, M.D., has been appointed as Executive Vice President of Research and Development.
Who to call at Noema Pharma, and when
A new leader at Noema Pharma brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Noema Pharma raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Noema Pharma, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Noema Pharma
Location
Basel, Basel City, Switzerland
About
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025.
Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT Life Sciences, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Noema Pharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BaselBiotechnologyHealth CareTherapeutics